Cell growth and differentiation are controlled by a complex interplay of signalling pathways functioning in an integrated, rather than sequential or parallel, fashion. Chemical genetics is based on the principle of using small molecular weight compounds to abrogate or enhance specific regulatory pathways, providing a powerful means of analysing complex regulatory systems. In the present study we used this approach to probe the signalling network involved in the control of Notch1 gene expression and function in human keratinocytes, skin and tumours.
Notch signalling has a key role in promoting keratinocyte differentiation and suppressing keratinocyte-derived tumours 1, 2 . Notch receptors, with Notch1 (A001670) and 2 being the main forms expressed in keratinocytes, are activated by consecutive cleavage by an ADAM metalloproteinase and a presenilin/γ-secretase complex. The resulting Notch intracellular domain (ICN) translocates to the nucleus where it associates with the DNA-binding protein CSL (CBF-1 or RBP-Jκ in mammalian cells), converting it from a repressor into an activator of transcription 3 . Binding of a second ancillary protein, Mastermind-like 1 (MAML1) or related family members, is required for sustained levels of Notch/CSLdependent transcriptional activation (through recruitment of further transcription co-activators such as p300; ref. 4) .
We recently showed that in primary human keratinocytes, genetic or pharmacological suppression of Notch signalling results in lesser commitment to differentiation, expansion of stem-cell populations and markedly increased susceptibility to ras-induced oncogenic conversion 2 . Similar effects were observed after pharmacological suppression of endogenous Notch activity by a γ-secretase inhibitor 2 . These findings are likely to be of clinical significance, as Notch1 gene expression and activity are substantially downmodulated in keratinocyte cancer cell lines and tumours, with expression of this gene being under positive p53 (A001721) control in these cells 2, 5 . EGFR (A000823) is among the most intensely studied and well understood determinants of epithelial cell proliferation, and EGFR inhibitors are outstanding examples of rational-based drug design for tumours control of differentiation. Here we report that this pathway has a role in the negative regulation of Notch1 gene transcription in both normally proliferating keratinocytes and cancer cells, which impinges on control of differentiation as well as apoptosis.
RESULTS

Negative regulation of Notch1 gene expression by EGFR/ERK signalling
Little is known of the pathways involved in upstream control of Notch1 gene expression and activity. To address this issue we undertook a chemical genetics approach. We chose a small library of compounds with established target selectivity, using a luciferase Notch/CSL-responsive reporter as read-out. The negative regulators of Notch signalling identified by this screen included inhibitors of matrix metalloproteinases and γ-secretase, which are required for endogenous Notch activation 4 , confirming the validity of the assay (Supplementary Information, Table S1 ). Statistical analysis of the results pointed to a number of other candidate pathways. In particular, the most significant compounds to induce Notch activity were kinase inhibitors that target components of signalling networks connected to EGFR signalling, which were of special interest, given the relevance of this pathway in keratinocytes and cancer 10, 11 . To validate the findings of our screen, we compared the effects of EGFR inhibition and stimulation on endogenous Notch signalling in human primary keratinocytes (HKCs). A concentration-response Figure 1 Negative control of Notch1 activity and expression by EGFR/ERK/ AP1 signalling. (a, b) Primary human keratinocytes (HKCs) were treated with AG1478 at the indicated concentrations or with recombinant EGF (1 ng ml -1 ) for 24 h. Hes1, Hes5 and Herp1 (a) and Notch1 (b) mRNA levels were quantified by real-time RT-PCR. Values are expressed as relative units after internal normalization for 36B4 mRNA levels, with similar results being obtained after normalization for β-actin mRNA. (c) HKCs were treated with AG1478 and EGF as in the previous panel, followed by immunoblot analysis for Hes1, total and activated Notch1 and Notch2, and γ-tubulin as equal loading control. (d) HKCs were transfected with two different siRNAs specific for EGFR, in parallel with scrambled siRNA control. Expression of the EGFR, Hes1 and Notch1 genes was assessed 48 h after transfection by real-time RT-PCR analysis (left panels), and confirmed at the protein level by immunoblotting (right panel). (e, f) HKCs were transfected with validated siRNAs for the indicated protein kinase (e) and transcription factor (f) genes, in parallel with scrambled siRNA control. Knockdown efficiency of >80% was obtained for each of these genes, as verified by real-time RT-PCR analysis with the corresponding specific primers 48 h after transfection (data not shown). Levels of Notch1 mRNA expression were assessed by real time RT-PCR analysis as in the previous panels. For ERK1, ERK2, c-Jun, c-Fos and ELK1, similar results were obtained after transfection with a second set of specific siRNAs. (g) HKCs, transfected with siRNA specific for c-Jun and scrambled siRNA control as in the previous panel, were analysed by immunoblotting for total Notch1; γ-tubulin was used as an equalloading control. Data were quantified by densitometric scanning, using relationship for the effects of the EGFR inhibitor AG1478 on EGFR, ERK1/2, c-Jun and Elk proteins, as well as c-Fos, was determined in HKCs. AG1478 decreased phosphorylation of EGFR, ERK1/2, c-Jun and Elk proteins, and caused downregulation of c-Fos, which is controlled by growth factors more indirectly at the level of gene transcription ( Supplementary Information, Fig. S1 ). At the same concentrations, there was induction of the canonical Notch target genes Hes1, Hes5 and Herp1, whereas EGF treatment suppressed expression of these genes (Fig. 1a) . In parallel with this effect, Notch1 mRNA levels were increased by EGFR inhibition, but downregulated by EGF treatment (Fig. 1b) .
Consistent with a transcriptional mechanism, no increase in Notch1 mRNA stability was observed in AG1478-treated cells after actinomycin D treatment (data not shown). The results were confirmed at the protein level by immunoblotting of AG1478-and EGF-treated keratinocytes with antibodies against total and cytoplasmic activated forms of Notch1, as well as Hes1 (Fig. 1c) . Effects similar to those of AG1478 were also elicited by erlotinib, an EGFR inhibitor approved for clinical use 12 ( Supplementary Information, Fig. S2 ). Besides chemical inhibition, upregulation of Notch1 activity and expression were also observed after knockdown of EGFR expression by transfection of keratinocytes with specific siRNAs (Fig. 1d) . In contrast to Notch1, Notch2 expression was modulated by EGFR signalling at the mRNA but not protein level (Supplementary Information, Figs S1c, S3a), and expression of the Notch ligands Jagged 1 and Delta-like 1 was not consistently changed ( Supplementary Information, Fig. S3b, c) .
EGFR suppression can cause growth inhibition and increased apoptosis 6, 13 , a finding that we confirmed experimentally, suggesting that induction of Notch1 expression is only an indirect consequence of these events. However, treatment of keratinocytes with TNF-α at pro-apoptotic concentrations had no effects on Notch1 expression, which was similarly unaffected by TGF-β-induced growth suppression ( Supplementary  Information, Fig. S2 ).
The ERK1/2 kinases and the AP-1 transcription complex function as downstream effectors of EGFR activation 10 . Induction of Notch1 gene expression similar to that caused by EGFR suppression was observed after siRNA-mediated knockdown of the MEK1 and ERK1 genes whereas, consistent with their proposed distinct functions in keratinocytes 14 , knockdown of MEK2 or ERK2 had no such effect (Fig. 1e) . In contrast to MEK1 and ERK1, no increase of Notch1 expression, or even suppression, was observed after knockdown and/or pharmacological inhibition of the p38 and JNK kinases, Akt and PKA ( Fig. 1e ; Supplementary Information, Fig. S2 ). Induction of Notch1 expression also occurred after knockdown of c-Jun and c-Fos, two key AP-1 family members ( Fig. 1f, g ). Even in this case, the effects were specific, as they were not observed after knockdown of other AP-1 family members, such as JunB, Jun D, Fra1 or Elk-1, a transcription factor which is activated by EGFR though an AP-1 independent mechanism 15 ( Fig. 1f) .
Modulation of Notch1 gene transcription by EGFR signalling through p53
We and others showed recently that the Notch1 gene is a direct transcriptional target of p53 in keratinocytes 2, 5, 16 . Consistent with these results, our chemical screen pointed to a p53 inhibitor, pifithrin, as a negative regulator of Notch signalling (Supplementary Information, Table S1 ), a finding which we confirmed directly by treating keratinocytes with this compound (data not shown). We therefore surmised that a p53-dependent mechanism is involved. To test this possibility, p53 expression was suppressed in HKCs by siRNA knockdown. This resulted in reduced levels of Notch1 expression already under basal conditions and, much more substantially, in response to EGFR knockdown (Fig. 2a) . Consistent with a p53-dependent transcriptional control mechanism, luciferase reporter activity of a 2.4 kbp Notch1 promoter region containing p53 binding sites 2, 5 , but not of a shorter region lacking these sites, was induced in HKCs after EGFR inhibition. This was abrogated by p53 knockdown (Fig. 2b) .
Endogenous p53 activity, as assessed by expression of well established targets, p21
WAF1/Cip1 and Gadd45α
17
, was induced by EGFR suppression ( Fig. 2c) . There was also a substantial increase in Mdm2, a negative regulator of p53 stability and itself a p53 target gene 17 ( Fig. 2d) . Consistent with the negative-feedback loop between p53 and Mdm2 protein expression, induction of p53 protein levels by AG1478 became much more evident in cells concomitantly treated with Nutlin, an Mdm2 inhibitor 18 ( Fig. 2e ). Emerging evidence indicates that transcription of this gene is important in the control of p53 activity [19] [20] [21] . Consistent with this possibility, real-time RT-PCR analysis showed that p53 mRNA levels were significantly increased as a consequence of EGFR inhibition but reduced by EGF treatment (Fig. 2f ). Previous work with mouse embryonic fibroblasts implicated c-Jun as a direct negative regulator of p53 gene transcription 22 . Consistent with this mechanism, chromatin immunoprecipitation experiments showed that endogenous c-Jun protein binds to a predicted AP-1 binding region of the p53 promoter in control keratinocytes, whereas such binding is abrogated in AG1478-treated cells (Fig. 2g) . Reporter assays showed that 26 were injected intraperitoneally with AG1478 (1 mg) or DMSO control every two days. Six days later, mice were analysed for GFP expression by immunofluorescence microscopy of back skin using anti-GFP antibodies. (b, c) Back skin epidermis of the same mice was separated from the underlying dermis by brief heat treatment. GFP transgene expression was determined by real-time RT-PCR in parallel with endogenous Notch1, p53 and keratin 1, with β-actin for normalization. (d) Back skin epidermis of homozygous wa-2 mice (with an EGFR mutation causing >90% decreased activity 44 ) and heterozygous littermates was analysed for p53 and Notch1 expression by real-time RT-PCR. (e) Skin biopsies from melanoma cancer patients following treatment with the MEK inhibitor AZD6244 (ARRY-142886; Astra Zeneca) were analysed in parallel with biopsies from age-and gendermatched controls for Notch1 expression by immunofluorescence microcopy with anti-Notch1 antibodies. Exposure and image-capture conditions were identical for all samples. Parallel immunostaining with anti-p53 antibodies demonstrated increased levels of this protein (data not shown and ref. 27 ). (f) Freshly excised human skin samples were placed in semi-solid medium and treated with DMSO control or AG1478 (10 µM) for 24 h. Histological sections were analysed by immunofluorescence microscopy with antibodies against Notch1. Arrows indicate the outermost layer of the epidermis and dotted line the innermost. Haematoxylin and eosin staining and immunofluorescence microscopy of parallel sections with anti-keratin1 antibodies are shown in Supplementary Information, Fig. S5a . (g): Human skin samples, as in the previous panel, were placed in semi-solid medium and treated with DMSO or AG1478 (10 µM) with or without DAPT (10 µM; black and white bars, respectively) for 24 h. Epidermis was separated from underlying dermis by brief heat treatment (60 °C, 45 s) followed by total RNA preparation and analysis of mRNA expression of the indicated genes by real-time RT-PCR, with β-actin for normalization.
p53 promoter activity was suppressed by increased c-Jun expression, whereas it was induced by c-Jun knockdown (Fig. 2h) , with a similar effect on endogenous p53 gene transcription (Fig. 2i) . The role of p53 in mediating control of Notch1 expression was demonstrated by the finding that induction of Notch1 expression by c-Jun knockdown was blocked by concomitant downmodulation of p53 (Fig. 2j) .
EGFR-p53-Notch control of differentiation in primary keratinocytes and intact skin EGFR signalling exerts an inhibitory effect on keratinocyte differentiation, whereas increased Notch activity promotes this process 1 . Downregulation of EGFR signalling, by either siRNA transfection or AG1478 treatment, induced expression of terminal differentiation markers, including keratin 1, 10 and involucrin ( Supplementary Information,  Fig. S4 and data not shown). To assess whether induction of differentiation by EGFR suppression is caused by upregulation of Notch signalling, primary human keratinocytes were infected with a retroviral vector expressing MAM51, a 51-amino-acid peptide that competes for MAML1 binding to the Notch-CBF-1 complex and prevents downstream transcription 23 . Treatment of MAM51-expressing keratinocytes with AG1478 caused a similar induction of Notch1 expression as that seen in control cells; by contrast, induction of Hes1 and differentiation markers was suppressed (Fig. 3a) . Chemical inhibitors of γ-secretase activity, such as DAPT, suppress proteolysis-dependent activation of endogenous Notch receptors 24 . As with MAM51 expression, treatment of HKCs with DAPT counteracted induction of Hes1 and differentiation marker expression caused by EGFR downregulation (Fig. 3b) . Similar counteracting effects were observed after knockdown of Notch1 and p53 expression, indicating that upregulation of these genes by EGFR inhibition is responsible for the observed induction of differentiation (Fig. 3c) . In Drosophila melanogaster, instead of being involved in direct inhibition of Notch activity and/or expression, EGFR signalling was reported to negatively regulate Groucho, a downstream effector of Notch (as well as other pathways) 25 . Such an indirect mechanism does not apply to our system. Indeed, EGFR activation exerted no counteracting effects on induction of differentiation by activated Notch1 (Fig. 3d ) and differentiation was suppressed rather than induced by Hes1, an effector of the mammalian homologue of Groucho (Fig. 3e) .
Growth and differentiation of keratinocytes in culture differs in significant aspects from that in intact skin. For further validation of our findings, we resorted to several complementary approaches. First, mice with a green fluorescent protein (GFP) reporter for Notch activity 26 were injected with AG1478. Immunofluorescence microscopy showed increased GFP expression in the epidermis of the AG1478-treated mice, compared with control mice (Fig. 4a) . For confirmation and quantification of the results, the epidermis of these mice was separated from the underlying dermis by brief heat treatment, followed by RNA preparation and real-time RT-PCR. This confirmed that GFP expression was increased, which paralleled increased expression of the endogenous Notch1, p53 and keratin 1 genes (Fig. 4b, c) . As a second approach, the epidermis of homozygous mice for a hypomorphic EGFR mutation was analysed in parallel with heterozygous littermates. Decreased EGFR activity was found to cause an increase in p53 and Notch1 expression (Fig. 4d) .
In humans, inhibitors of the EGFR pathway are now used for treatment of several types of cancer 6, 12 . Immunofluorescence microscopy of skin biopsies from melanoma patients treated with the MEK inhibitor AZD6244, compared with matched controls, showed consistent upregulation of Notch1 expression (Fig. 4e) , which paralleled that of p53 (ref. 27 and data not shown). Similar results were obtained with an organ culture system of freshly excised human skin. Immunohistochemical analysis, as well as real-time RT-PCR, indicated that even in this case, EGFR inhibition caused induction of Notch1 and p53 expression and activity, together with differentiation ( Fig. 4f; Supplementary Information,  Fig. S5 ). Induction of differentiation by EGFR inhibition was Notchdependent, as it was counteracted by concomitant treatment with DAPT, whereas, as expected, induction of the Notch1 gene itself, or of p53, was unaffected or even increased (Fig. 4g) .
Inhibition of EGFR signalling in cancer cells induces Notch1 gene expression through p53
To assess whether the above findings apply to conditions where EGFR signalling has been causally linked with cancer development, we analysed transgenic mice expressing an active form of the EGFR/Ras adaptor protein SOS under the control of a keratin 5 promoter (K5-SOS-F). These mice (Fig. 5a ). Results were confirmed at the protein level by immunoblotting of a separate set of tumours, as well as by immunofluorescence microscopy for Notch1 expression (Fig. 5b, c) .
To assess whether similar EGFR regulation of Notch1 expression applies to human cancer, keratinocyte-derived SCC cells (SCCO28, SCC12 and SCC13) with wild-type p53 (http://www.sanger.ac.uk/genetics/CGP/ CellLines/) were treated with AG1478. Besides mutations, p53 activity can also be reduced in tumours as a consequence of decreased p53 gene transcription 21, [30] [31] [32] [33] . Consistent with this mode of regulation, EGFR inhibition of SCC cells induced expression of the p53 gene as well as of p21 WAF1/
Cip1
, indicative of increased p53 activity (Fig. 6a, b) . This was paralleled by a substantial increase in Notch1 mRNA and protein levels and differentiation markers ( Fig. 6c, d; Supplementary Information, Fig. S6a) . As with HKCs, p53 knockdown experiments showed that even in cancer cells, induction of Notch1 expression by EGFR-inhibition is p53-dependent (Fig. 6e) .
Cancer cell lines can differ substantially in their control mechanisms from cells in primary tumours. Therefore, as a further validation of our findings, the same organ culture system described above for intact skin was adapted to the analysis of clinically occurring SCCs freshly excised from patients. In five independent tumours, EGFR inhibition resulted in reduction of c-Fos expression, indicative of EGFR signalling suppression, and concomitant induction of Notch1, p53 and keratin 1 ( Fig. 6f;  Supplementary Information, Fig. S6c ). In four other tumours no such effects were observed, consistent, in two cases, with resistance of EGFR inhibition (as assessed by no decrease in c-Fos expression) and, in the other two, undetectable p53 expression or activity (data not shown).
Inhibition of Notch signalling in cancer cells suppresses differentiation induced by EGFR suppression while it synergizes for apoptosis
As with HKCs, inhibition of EGFR signalling in SCC cells caused upregulation of differentiation marker expression through a Notch-dependent mechanism ( Supplementary Information, Fig. S6a, b) . We have recently found that Notch-dependent differentiation of keratinocytes renders these cells more resistant to apoptosis 16 . Thus, an attractive possibility was that suppression of Notch signalling, while suppressing the prodifferentiation effects of EGFR inhibitors, may synergize with these compounds in triggering apoptosis. When SCC cells were treated with DAPT and AG1478, apoptosis was increased substantially (Fig. 7a) . These findings were paralleled by a synergistic induction of Bim1 expression (Fig. 7b) , a pro-apoptotic Bcl2 family member recently implicated in the cancer cell response to EGFR inhibitors 34 .
To further validate the relevance of these findings for the behaviour of cancer cells in vivo, immunocompromised mice were injected with SCC cells expressing the Notch inhibitory MAM51 peptide, in parallel with control cells. After formation of sizable tumours (4 weeks after injections), mice were treated with AG1478 for a week. RT-PCR analysis of tumour RNAs showed substantially higher levels of Hes1 and differentiation marker expression in tumours formed by control than MAM51-expressing cells, whereas levels of Bim1 were oppositely regulated (Fig. 7c) . This was paralleled by a higher apoptotic fraction in tumours with suppressed Notch signalling (Fig. 7d) .
DISCUSSION
EGFR signalling has a key role in the positive control of keratinocyte growth potential and carcinogenesis 9 . We have shown here that EGFR signalling, as well as enhancing proliferation, has a significant role in suppressing differentiation through negative regulation of Notch1 gene expression and activity. This mechanism is likely to prevent the commitment to differentiation of keratinocytes in the basal proliferative compartment of the epidermis as well as in cancer, where EGFR signalling is characteristically elevated 9 .
In the upper epidermal layers, EGFR signalling is normally downregulated and therefore ceases to be relevant. Indeed, differentiation of keratinocytes as they migrate to the upper epidermal layers is induced by multiple EGFR-unrelated events including, most notably, loss of integrin-mediated adhesion to the matrix and establishment of cadherin-dependent cell-cell adhesion 35 . This is also consistent with control of the Notch1 gene by p53 being relevant for the behaviour of proliferating keratinocytes in normal skin and cancer 2, 5, 16 , whereas additional multiple mechanisms are responsible for the increase in Notch signalling in normally differentiating keratinocytes of the upper epidermal layers 1 .
The cross-talk between the Notch and EGFR signalling has been well documented in genetic model systems where these pathways can be either antagonistic or synergistic, depending on tissue and developmental contexts 36 . We have shown here that EGFR signalling functions in the negative control of Notch1 gene expression, through a mechanism involving transcriptional downregulation of the p53 gene. Previous studies have indicated that NF-κB controls p53 gene expression 37 , which could be of relevance to the present situation, as NF-κB activity is induced in keratinocytes with differentiation 38 , whereas its suppression promotes tumour development 39 . However, expression of NF-κB-responsive genes, as an indication of endogenous activity, is not induced in keratinocytes by EGFR suppression (data not shown). An alternative control mechanism is provided by AP-1 family members. Among these, c-Jun can either activate or suppress direct target genes 40 . Previous work with mouse embryo fibroblasts has implicated c-Jun as a direct negative regulator of p53 gene expression 22 . Consistent with this mechanism, endogenous c-Jun binds to the p53 promoter in both normal and SCCderived keratinocytes, and expression of the p53 gene in these cells is enhanced by c-Jun knockdown. Notch1 expression is also induced by c-Jun knockdown, in a p53-dependent fashion. This concomitant mode of regulation of p53/Notch1 expression by EGFR signalling is further validated by our findings with organ cultures of intact human skin and SCCs, as well as a mouse model of skin cancer formation dependent on EGFR and c-Jun function.
EGFR has become an important target of cancer drug design, and several selective EGFR inhibitors have now been approved for clinical use. Recent data have highlighted the fact that inhibitors directed to critical receptors like EGFR use the cell-death pathway for inducing tumour regression 34 . However, the exact molecular mechanisms underlying sensitivity and resistance of tumour cells to EGFR inhibition, including the contribution of other integrated pathways, such as those identified here, remain to be elucidated 41 . Importantly, suppression of Notch signalling in SCCs counteracts the differentiation-inducing effects of EGFR inhibitors, while, at the same time, synergizing with these compounds in induction of apoptosis. Other ongoing studies in the laboratory indicate that the enhancing effects of Notch suppression on apoptosis may extend also to lung cancer cells. This suggests an attractive new avenue of combination cancer therapy that may enhance the potency of EGFR inhibitory agents on tumours, while at the same time ameliorating their well known toxic effects on the skin, which have been attributed, at least in part, to aberrant differentiation 11 . . Adenoviruses for Notch1, Hes1 and GFP, and adenoviral infections were previously described 38 . Chemical inhibitors, AG1478 (LC Labs), Nutlin (Calbiochem), DAPT (Calbiochem), ERK inhibitory peptide-cell permeable (Calbiochem) were dissolved in DMSO and applied at the indicated concentrations. For knockdown experiments, cells were transfected as described previously 38 with validated stealth siRNAs for human EGFR, p53, c-Fos and c-Jun in parallel with corresponding Stealth siRNA controls (Invitrogen), or ERK1, ERK2 and Notch1 (GeneGlobe, Qiagen), and analysed 48-72 h after transfection. siRNA sequences are presented in Supplementary Information , Table S3 . The Notch1 promoter regions -2472/-1 and -392/-1 (numbered referred to the ATG) were amplified by PCR from human genomic DNA with the primer pairs 5´-CTGCCTCCCGACCTGTAGGAG-3´ and
METHODS
a n d 5´-GCCTCCCCACCGGCTGCCCTC-3´, and subcloned into the of pGL4 vector (Promega) using the KpnI/NheI sites. The two promoter regions were inserted into lentivector pTRH4-mCMV-Luc (System Biosciences) at the EcoRI/SpeI sites. Lentiviruses were produced as described before 42 Luciferase assays, quantitative real-time RT-PCR, chromatin immunoprecipitation (ChIP) and immunodetection techniques. Conditions for luciferase assays, real-time RT-PCR analysis, ChIP, immunoblotting and immunofluorescence microscopy were performed as described previously 2 . The list of gene-specific primers is provided in Supplementary Information, Table S2 . We used the following antibodies: Notch1 (C-20, 1:500; Santa Cruz), activated Notch1 (1:1000; Cell Signaling), Hes1 (1:500; Chemicon AB5702), keratin1 (1:5000; Babco AF87), involucrin (1:5000; Babco PRB140C), EGFR (1:1000; Cell Signaling), p53 (1:1000; Cell Signaling), MDM2 (1:1000; Cell Signaling), integrin β4 (1:500; Santa Cruz) and γ-tubulin (1:5000; Sigma GTU87), and for immunoblotting for mouse proteins: Notch1 (1:500; Pharmingen), p53 (1:1000; Novacastra), c-Jun (1:500; Transduction Labs) and actin (Sigma), and c-Jun for Chip assays (1:500; Santa Cruz, H79).
Organ cultures. Discarded human skin samples from abdominoplasty procedures were obtained from the Centre Hospitalier -Universitaire Vaudois (Lausanne, Switzerland) with patient consent and institutional approval. Skin samples, sterilized in 70% ethanol and cut, after removal of subcutaneous fat, into 1 × 1cm pieces, were placed in keratinocyte serum-free medium (KSF, GIBCO-BRL) supplemented with EGF and bovine pituitary extract (BPE), in 0.25% agar (Sigma). The epidermis was maintained at the air-medium interface. For RNA collection, skin samples were placed in preheated PBS at 60 °C for 45 s, then chilled (on ice) in 0.1 M PBS for 1 min, followed by mechanical separation of the epidermis and dermis. The epidermis was homogenized in TRI reagent (Sigma) for RNA preparation. Human SCC samples were obtained as discarded material from Mohs Micrographic Surgery at Massachusetts General Hospital (Boston, MA) with patient consent and institutional approvals. Tumour samples were sterilized in 70% ethanol, cut into pieces of approximately 2 × 2 mm and placed in semi-solid medium similarly to skin organ cultures.
Tumorigenicity assays. For in vivo tumorigenicity assays, control and MAM51-expressing SCCO28 cells were brought into suspension, admixed with Matrigel (BD Biosciences), and injected (5 × 10 6 cells per injection) subcutaneously into 8-week-old female athymic nude mice. Four weeks later, animals were treated three times (every other day) with AG1478 (1 mg per animal, dissolved in 200 µl 50% DMSO:DMEM) or DMSO vehicle control by intraperitoneal injections. Mice were killed two days after the last treatment and tumours processed for RNA preparation and analysis.
TUNEL assays. Cells were trypsinized, recovered by centrifugation at 300g and fixed in 2% paraformaldehyde in PBS for 16 h. Permeabilization and enzymatic labelling with TMR red-conjugated-dUTP were performed according to the manufacturer's protocol (Roche). The percentage of cells that incorporated the fluorescence-conjugated dUTP was determined by flow cytometry. TUNEL assay on histological sections was analysed with fluorescence microscopy and IPLab software.
Statistical analysis. In all histograms, results of real-time RT-PCR and luciferase assays are presented as mean ± s.d., all assays being performed in triplicate wells (n = 3) with internal normalization, with similar results being observed in two or more independent experiments. 
